| 4888 | study 101 dose finding, 2020 | 2 | 31 | 0 | excluded | not a RCT | risk of bias not avaialble |
| 6052 | BioNTech phase 2 (Walsh), 2020 | 2 | 1 | 0 | excluded | risk of bias not avaialble | |
| 6054 | Moderna preclinical (Corbett), 2020 | 2 | 1 | 0 | excluded | risk of bias not avaialble | |
| 6766 | Pfizer 16-25 years phase 3, 0 | 2 | 1 | 0 | excluded | risk of bias not avaialble | |
| 6966 | Ou, 2021 | 2 | 32 | 0 | excluded | not a RCT | risk of bias not avaialble |
| 8248 | Montgomery, 2021 | 2 | 13 | 0 | excluded | not a RCT | risk of bias not avaialble |
| 9065 | Ruddy, 2021 | 2 | 32 | 0 | excluded | not a RCT | risk of bias not avaialble |
| 9230 | Burns, 2022 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 9445 | Kawasuji, 2022 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 9466 | Falsey, 0 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 9485 | Molteni, 2022 | 2 | 0 | 0 | excluded | risk of bias not avaialble |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
